NRW.Bank

NRW.BANK is the development bank for the state of North Rhine-Westphalia, established in 2002 and headquartered in Düsseldorf, Germany. The bank focuses on supporting small and medium-sized enterprises, as well as local authorities, by providing a wide range of banking products and services. It specializes in low-interest promotion loans, equity financing, and advisory services, aimed at fostering economic, social, and housing development. NRW.BANK combines various funding programs from the state, federal government, and European Union with its own financial solutions. Its operations encompass key sectors such as economy, housing, and infrastructure, offering comprehensive support for business start-ups, expansions, urban development, and initiatives in environmental protection and innovation. By acting as a neutral partner to banks and savings institutions, NRW.BANK plays a crucial role in enhancing the region's economic landscape.

Matthias Bolowski

Investment Manager

Past deals in Germany

Valuedesk

Series A in 2024
Valuedesk GmbH is a service company based in Bielefeld, Germany, that specializes in structured savings and efficiency management. Founded in 2017, Valuedesk provides a comprehensive solution that enables organizations to record, analyze, and implement improvements and savings across various industries, including automotive, biotechnology, energy, food, furniture, construction, chemicals, IT, logistics, telecommunications, electronics, pharmaceuticals, and textiles. The company's adaptable system focuses on cost optimization, utilizing methodologies, workshops, and seminars to enhance transparency and communication within teams. By applying systematic approaches and technology, Valuedesk helps clients identify hidden savings and optimization potentials, develop tailored implementation concepts, and achieve long-term profitability.

Sphingotec GmbH

Series C in 2024
Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

CryoTherapeutics

Series B in 2024
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.

Resolve BioSciences

Series B in 2022
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's technology offers a comprehensive, high-resolution view of subcellular gene expression activities, which is crucial for advancements in various fields such as oncology, neuroscience, and infectious diseases. Resolve BioSciences provides a range of services and expertise in bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among other areas. This innovative approach supports researchers in their efforts to explore complex biological systems and improve outcomes in health and agriculture.

icho

Seed Round in 2022
icho systems gmbh, based in Duisburg, Germany, specializes in developing interactive therapy solutions for individuals with neurological conditions, particularly dementia, stroke, and Parkinson's disease. The company's flagship product, the ichó therapy ball, employs advanced sensor technology to respond to user interactions—such as rolling, catching, or shaking—with colored lights, sounds, and vibrations. This innovative device is designed to enhance cognitive and motor skills through engaging therapeutic activities, offering over 150 guideline-compliant therapy applications developed in collaboration with healthcare professionals. Since its introduction in 2020, the ichó therapy ball has been implemented in more than 850 facilities, and in 2023, it received funding as a preventive service under care insurance provisions. ichó aims to facilitate outpatient care for patients, ensuring effective therapeutic support in home settings. The product can be purchased directly from the company's website.

Einhundert

Venture Round in 2022
Einhundert Energy, founded in 2017 and headquartered in Cologne, Germany, specializes in providing green and digital energy solutions for tenants and property managers. The company offers a comprehensive service package that includes the planning, installation, operation, and maintenance of photovoltaic systems, allowing tenants to access low-cost solar energy. Einhundert Energy also features a digital billing platform that provides transparent monthly billing based on actual power consumption, enabling users to monitor and manage their energy usage through a dedicated app. This system allows for seamless integration with various technologies, including heat and water billing, smoke detectors, heat pumps, and e-charging stations, contributing to consistent cost transparency and efficient energy management.

Emergence Therapeutics

Series A in 2021
Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.

Lumoview Building Analytics

Convertible Note in 2021
Lumoview Building Analytics GmbH, founded in 2019 and based in Cologne, Germany, specializes in developing an indoor measurement system for automated building analysis. The company's technology allows for rapid digitization of buildings, completing the process in just two seconds per room. Using a user-friendly device, Lumoview collects data that is then analyzed in the cloud through a highly automated platform. This connected online system enables building owners to make informed decisions to enhance their properties and reduce CO2 emissions, ultimately contributing to more efficient and sustainable building management.

aifora

Seed Round in 2021
aifora GmbH is a software company based in Düsseldorf, Germany, founded in 2017. It specializes in developing a platform that predicts consumer behavior and offers automation solutions for retail companies. The company's software utilizes big data and machine learning to provide services such as price optimization and inventory management, helping retailers make informed decisions about order quantities and merchandise distribution. By leveraging deep learning algorithms, aifora enables businesses to create customer-centric merchandising strategies, optimize pricing, and manage promotional activities effectively. The platform aims to improve profitability and enhance customer experiences while fostering a shared data ecosystem among brands and retailers. Through intelligent automation, aifora reduces the burden of repetitive tasks, allowing merchandisers to concentrate on product innovation and enhancing consumer engagement.

Semalytix

Series A in 2021
Semalytix GmbH, founded in 2015 and headquartered in Bielefeld, Germany, specializes in developing an artificial intelligence-driven platform designed to extract and summarize trends in the perception of high-cost therapies, particularly in oncology, immunology, and metabolism. The company's flagship tool, Pharos, serves as a real-world evidence generation solution that ingests data from various sources such as CRM systems, social media, job advertisements, and clinical studies. By processing information from patient forums and online discussions, Semalytix organizes this data to provide the pharmaceutical industry with valuable insights. This enables the medical community to make informed decisions that can improve treatment outcomes and enhance the understanding of patient experiences with medications.

Lumoview Building Analytics

Convertible Note in 2020
Lumoview Building Analytics GmbH, founded in 2019 and based in Cologne, Germany, specializes in developing an indoor measurement system for automated building analysis. The company's technology allows for rapid digitization of buildings, completing the process in just two seconds per room. Using a user-friendly device, Lumoview collects data that is then analyzed in the cloud through a highly automated platform. This connected online system enables building owners to make informed decisions to enhance their properties and reduce CO2 emissions, ultimately contributing to more efficient and sustainable building management.

icho

Funding Round in 2020
icho systems gmbh, based in Duisburg, Germany, specializes in developing interactive therapy solutions for individuals with neurological conditions, particularly dementia, stroke, and Parkinson's disease. The company's flagship product, the ichó therapy ball, employs advanced sensor technology to respond to user interactions—such as rolling, catching, or shaking—with colored lights, sounds, and vibrations. This innovative device is designed to enhance cognitive and motor skills through engaging therapeutic activities, offering over 150 guideline-compliant therapy applications developed in collaboration with healthcare professionals. Since its introduction in 2020, the ichó therapy ball has been implemented in more than 850 facilities, and in 2023, it received funding as a preventive service under care insurance provisions. ichó aims to facilitate outpatient care for patients, ensuring effective therapeutic support in home settings. The product can be purchased directly from the company's website.

COMPEON

Series C in 2020
COMPEON is a leading financing portal in Germany that specializes in providing small and medium-sized enterprises (SMEs) with tailored financial solutions. By submitting a query on their website, companies can receive customized offers from over 220 banks, leasing companies, and other financial providers at no cost. Annually, COMPEON processes financing inquiries totaling €2.5 billion, offering a diverse range of products including loans, leasing agreements, factoring, mezzanine capital, and project financing. Established in 2013, the company is managed by its founders—Kai Böringschulte, Dr. Nico Peters, and Dr. Frank Wüller—and is backed by investors such as DvH Ventures, b-to-v, and Tengelmann Ventures. Through its online platform, COMPEON enables SMEs to efficiently compare and secure the financial products they need to support their growth and projects.

Ubirch

Seed Round in 2020
Ubirch GmbH, founded in 2014 and based in Cologne, Germany, specializes in developing Internet of Things (IoT) software security solutions utilizing blockchain technology. The company offers a platform that enables the secure transmission and sharing of carbon footprint data, allowing businesses to subscribe and calculate their share of emissions. Ubirch's systems cryptographically sign carbon disclosures, facilitating their reuse within a network and enhancing transparency. This approach addresses the growing importance of climate reduction measures for companies aiming to meet environmental, social, and governance (ESG) criteria. Ubirch serves various industries, including production, insurance, energy, and logistics, helping organizations compile their Scope 3 carbon footprints in an auditable manner.

Lumoview Building Analytics

Funding Round in 2020
Lumoview Building Analytics GmbH, founded in 2019 and based in Cologne, Germany, specializes in developing an indoor measurement system for automated building analysis. The company's technology allows for rapid digitization of buildings, completing the process in just two seconds per room. Using a user-friendly device, Lumoview collects data that is then analyzed in the cloud through a highly automated platform. This connected online system enables building owners to make informed decisions to enhance their properties and reduce CO2 emissions, ultimately contributing to more efficient and sustainable building management.

Einhundert

Venture Round in 2018
Einhundert Energy, founded in 2017 and headquartered in Cologne, Germany, specializes in providing green and digital energy solutions for tenants and property managers. The company offers a comprehensive service package that includes the planning, installation, operation, and maintenance of photovoltaic systems, allowing tenants to access low-cost solar energy. Einhundert Energy also features a digital billing platform that provides transparent monthly billing based on actual power consumption, enabling users to monitor and manage their energy usage through a dedicated app. This system allows for seamless integration with various technologies, including heat and water billing, smoke detectors, heat pumps, and e-charging stations, contributing to consistent cost transparency and efficient energy management.

Unu motors

Series B in 2018
Unu GmbH, founded in 2013 and headquartered in Berlin, Germany, specializes in the design, development, and sale of electric scooters. The company aims to enhance urban mobility by providing stylish, emission-free, and quiet scooters that feature portable batteries, allowing users to charge them conveniently at home. Unu's first electric scooter was launched in 2014, marking the beginning of its commitment to connecting people with their cities. In addition to selling scooters through retail outlets and online, the company offers various financing options and after-sales support services to enhance customer experience.

icho

Seed Round in 2018
icho systems gmbh, based in Duisburg, Germany, specializes in developing interactive therapy solutions for individuals with neurological conditions, particularly dementia, stroke, and Parkinson's disease. The company's flagship product, the ichó therapy ball, employs advanced sensor technology to respond to user interactions—such as rolling, catching, or shaking—with colored lights, sounds, and vibrations. This innovative device is designed to enhance cognitive and motor skills through engaging therapeutic activities, offering over 150 guideline-compliant therapy applications developed in collaboration with healthcare professionals. Since its introduction in 2020, the ichó therapy ball has been implemented in more than 850 facilities, and in 2023, it received funding as a preventive service under care insurance provisions. ichó aims to facilitate outpatient care for patients, ensuring effective therapeutic support in home settings. The product can be purchased directly from the company's website.

Holocafé

Seed Round in 2018
Holocafé ist a franchiser company developing exclusive, shared-space VR experiences for location-based entertainment. Content aside, we have developed an entire one-stop platform solution to provide leisure operators with all tools they need: From ticketing and online payment over staff scheduling and accounting to store automization and content distribution. We are presently running three pilot stores in Germany with a fourth one scheduled to open this spring, in addition to a number of international licensees.

Hemovent

Series A in 2017
​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop an innovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.

Unu motors

Series A in 2017
Unu GmbH, founded in 2013 and headquartered in Berlin, Germany, specializes in the design, development, and sale of electric scooters. The company aims to enhance urban mobility by providing stylish, emission-free, and quiet scooters that feature portable batteries, allowing users to charge them conveniently at home. Unu's first electric scooter was launched in 2014, marking the beginning of its commitment to connecting people with their cities. In addition to selling scooters through retail outlets and online, the company offers various financing options and after-sales support services to enhance customer experience.

CryoTherapeutics

Series B in 2016
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.

Hemovent

Series A in 2016
​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop an innovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.

CEVEC Pharmaceuticals

Venture Round in 2015
CEVEC Pharmaceuticals GmbH specializes in the manufacture of biopharmaceutical molecules featuring human glycosylation patterns. The company develops the CAP-GO platform, which includes optimized expression vectors and a cell line generation process that is free from serum and animal components. This platform enables the efficient production of complex, glycosylated proteins and therapeutic proteins, including monoclonal antibodies. CEVEC also offers the CAP-GT platform for the industrial-scale production of gene therapy vectors, such as Lentiviral, Adenoviral, and AAV types. Additionally, the company provides contract manufacturing services. Founded in 2001 and based in Cologne, Germany, CEVEC has established a strategic collaboration with BioLamina AB to enhance its capabilities in biopharmaceutical production.

Vimecon

Venture Round in 2014
Vimecon GmbH, founded in 2005 and headquartered in Herzogenrath, Germany, specializes in the development and production of laser catheters specifically designed for the treatment of heart diseases, with a primary focus on atrial fibrillation. The company also manufactures a range of products for the medical technology and biotechnology sectors, including microscopically small catheters and micro materials handling techniques that facilitate precise measurement and dosage. Additionally, Vimecon provides advisory services to various clients in both academic and industrial research and development. Its innovations aim to enhance healthcare outcomes and support advancements in the treatment of cardiovascular diseases and cardiac arrhythmias.

CryoTherapeutics

Series A in 2014
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.

GreenPocket

Series B in 2012
GreenPocket GmbH, founded in 2009 and based in Cologne, Germany, specializes in energy management software designed for utility companies. The company provides solutions for interpreting and visualizing smart metering data, including a household customer portal and energy management software tailored for commercial clients. Their offerings encompass various tools such as a web portal for real-time energy consumption visualization, a business customer portal for cost-saving comparisons, and smart home solutions that optimize the control of household appliances. By leveraging innovative technologies like artificial intelligence and data science, GreenPocket aims to create significant value from smart meter data, thereby supporting energy suppliers and corporate customers in the transition towards a more sustainable energy future. With experience in over 125 projects across 12 countries, GreenPocket is positioned as a trusted partner in the digitalization of the energy industry.

Azeti

Series A in 2011
Azeti GmbH, based in Berlin, Germany, specializes in Internet of Things (IoT) software solutions that enable industrial companies to optimize their data management and infrastructure. Founded in 2006 and operating as a subsidiary of Aurubis AG since July 2020, Azeti provides a range of M2M solutions, including the SONARPLEX product line, which supports logistics companies in monitoring vehicle conditions, fuel consumption, and driver activities in real-time. The company also offers SonarWise for connecting remote cell sites to network operations, SONARMANAGER as a centralized application for managing appliances, and the azeti Lab app for mobile access. Its Social Sensor Cloud facilitates interaction among sensors and actuators, while the platform supports applications in telecommunications, data centers, and transportation. By delivering tailored solutions and fostering long-term customer relationships, Azeti has successfully implemented numerous projects across diverse industries, focusing on condition monitoring, predictive maintenance, and performance analysis.

CEVEC Pharmaceuticals

Venture Round in 2011
CEVEC Pharmaceuticals GmbH specializes in the manufacture of biopharmaceutical molecules featuring human glycosylation patterns. The company develops the CAP-GO platform, which includes optimized expression vectors and a cell line generation process that is free from serum and animal components. This platform enables the efficient production of complex, glycosylated proteins and therapeutic proteins, including monoclonal antibodies. CEVEC also offers the CAP-GT platform for the industrial-scale production of gene therapy vectors, such as Lentiviral, Adenoviral, and AAV types. Additionally, the company provides contract manufacturing services. Founded in 2001 and based in Cologne, Germany, CEVEC has established a strategic collaboration with BioLamina AB to enhance its capabilities in biopharmaceutical production.

Vimecon

Venture Round in 2011
Vimecon GmbH, founded in 2005 and headquartered in Herzogenrath, Germany, specializes in the development and production of laser catheters specifically designed for the treatment of heart diseases, with a primary focus on atrial fibrillation. The company also manufactures a range of products for the medical technology and biotechnology sectors, including microscopically small catheters and micro materials handling techniques that facilitate precise measurement and dosage. Additionally, Vimecon provides advisory services to various clients in both academic and industrial research and development. Its innovations aim to enhance healthcare outcomes and support advancements in the treatment of cardiovascular diseases and cardiac arrhythmias.

simfy

Venture Round in 2011
simfy GmbH operates as an online music platform. The company allows to share and store music online, as well as to listen instantly to specific tracks or albums via true on demand streaming. simfy GmbH was founded in 2006 and is based in Cologne, Germany.

Fashionette

Venture Round in 2011
Fashionette AG is an online retailer specializing in fashion accessories across Europe, offering a wide range of products including handbags, shoes, sunglasses, watches, and jewelry. Founded in 2008 and headquartered in Düsseldorf, Germany, the company focuses on providing customers with a curated selection of luxury items. With a commitment to quality and style, Fashionette has established itself as a prominent player in the online fashion market, catering to a diverse clientele seeking fashionable accessories.

simfy

Venture Round in 2010
simfy GmbH operates as an online music platform. The company allows to share and store music online, as well as to listen instantly to specific tracks or albums via true on demand streaming. simfy GmbH was founded in 2006 and is based in Cologne, Germany.

DIREVO Industrial Biotechnology

Series D in 2010
Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

CEVEC Pharmaceuticals

Series B in 2010
CEVEC Pharmaceuticals GmbH specializes in the manufacture of biopharmaceutical molecules featuring human glycosylation patterns. The company develops the CAP-GO platform, which includes optimized expression vectors and a cell line generation process that is free from serum and animal components. This platform enables the efficient production of complex, glycosylated proteins and therapeutic proteins, including monoclonal antibodies. CEVEC also offers the CAP-GT platform for the industrial-scale production of gene therapy vectors, such as Lentiviral, Adenoviral, and AAV types. Additionally, the company provides contract manufacturing services. Founded in 2001 and based in Cologne, Germany, CEVEC has established a strategic collaboration with BioLamina AB to enhance its capabilities in biopharmaceutical production.

DIREVO Industrial Biotechnology

Venture Round in 2010
Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

CEVEC Pharmaceuticals

Series A in 2009
CEVEC Pharmaceuticals GmbH specializes in the manufacture of biopharmaceutical molecules featuring human glycosylation patterns. The company develops the CAP-GO platform, which includes optimized expression vectors and a cell line generation process that is free from serum and animal components. This platform enables the efficient production of complex, glycosylated proteins and therapeutic proteins, including monoclonal antibodies. CEVEC also offers the CAP-GT platform for the industrial-scale production of gene therapy vectors, such as Lentiviral, Adenoviral, and AAV types. Additionally, the company provides contract manufacturing services. Founded in 2001 and based in Cologne, Germany, CEVEC has established a strategic collaboration with BioLamina AB to enhance its capabilities in biopharmaceutical production.

Innolume

Series C in 2008
Innolume GmbH is a manufacturer of advanced laser diodes based in Dortmund, Germany. Established in 2002, the company specializes in a wide array of optoelectronic devices, including single-mode and broad-area laser diodes, comb-lasers, and semiconductor optical amplifiers. Innolume's products are designed for various applications, such as Raman amplification, optical interconnects, and medical and industrial uses. Notably, the company has developed a novel comb laser light engine that facilitates economical wavelength-division multiplexing for short-reach optical connections in computing environments. This innovation enhances efficiency by reducing the need for multiple lasers and underutilized fiber, significantly lowering costs and power consumption. Innolume has also received recognition for its temperature-independent distributed feedback laser, which has the potential to impact the future of data communication.

DIREVO Industrial Biotechnology

Series C in 2007
Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

Innolume

Series B in 2006
Innolume GmbH is a manufacturer of advanced laser diodes based in Dortmund, Germany. Established in 2002, the company specializes in a wide array of optoelectronic devices, including single-mode and broad-area laser diodes, comb-lasers, and semiconductor optical amplifiers. Innolume's products are designed for various applications, such as Raman amplification, optical interconnects, and medical and industrial uses. Notably, the company has developed a novel comb laser light engine that facilitates economical wavelength-division multiplexing for short-reach optical connections in computing environments. This innovation enhances efficiency by reducing the need for multiple lasers and underutilized fiber, significantly lowering costs and power consumption. Innolume has also received recognition for its temperature-independent distributed feedback laser, which has the potential to impact the future of data communication.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.